Cargando…

Budget impact analysis of darolutamide for treatment of nonmetastatic castration-resistant prostate cancer

BACKGROUND: Darolutamide, a structurally distinct androgen receptor inhibitor approved for the treatment of men with nonmetastatic castration-resistant prostate cancer (nmCRPC), has been shown to increase metastasis-free survival among men with nmCRPC compared with placebo. This treatment has a nove...

Descripción completa

Detalles Bibliográficos
Autores principales:	Appukkuttan, Sreevalsa, Farej, Ryan, Miles, LaStella, Purser, Molly, Wen, Lonnie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10394191/ https://www.ncbi.nlm.nih.gov/pubmed/33141615 http://dx.doi.org/10.18553/jmcp.2020.20330

Ejemplares similares

Darolutamide: a novel androgen-signaling agent in nonmetastatic castration-resistant prostate cancer
por: Aragon-Ching, Jeanny B
Publicado: (2019)

Patient and caregiver benefit‐risk preferences for nonmetastatic castration‐resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

The ARAMIS trial: Why Darolutamide is better than apalutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer
por: Tripathy, Sambit
Publicado: (2021)

Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review
por: Cattrini, Carlo, et al.
Publicado: (2022)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Darolutamide For Castration-Resistant Prostate Cancer
por: Bastos, Diogo A, et al.
Publicado: (2019)

Survival Outcomes by Race and Ethnicity in Veterans With Nonmetastatic Castration-Resistant Prostate Cancer
por: Rasmussen, Kelli M., et al.
Publicado: (2023)

Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial
por: Uemura, Hiroji, et al.
Publicado: (2020)

Nonmetastatic Castration-Resistant Prostate Cancer
por: Hong, Jun Hyuk, et al.
Publicado: (2014)

Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2020)

Clinical outcomes, management, and treatment patterns in patients with metastatic castration‐resistant prostate cancer treated with radium‐223 in community compared to academic settings
por: Sartor, Oliver, et al.
Publicado: (2021)

Correction to: Darolutamide: A Review in Non-Metastatic Castration-Resistant Prostate Cancer
por: Scott, Lesley J.
Publicado: (2022)

Physician preferences for non-metastatic castration-resistant prostate cancer treatment
por: Srinivas, Sandy, et al.
Publicado: (2020)

A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use
por: Appukkuttan, Sreevalsa, et al.
Publicado: (2019)

Apalutamide for the Treatment of Nonmetastatic Castration-Resistant Prostate Cancer
por: Patel, Urvi J., et al.
Publicado: (2019)

Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
por: Fujmoto, Saizo, et al.
Publicado: (2022)

Darolutamide for prostate cancer
Publicado: (2020)

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Real-world burden of adverse events for apalutamide- or enzalutamide-treated non-metastatic castration-resistant prostate cancer patients in the United States
por: Hussain, Arif, et al.
Publicado: (2022)

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial
por: Shore, Neal, et al.
Publicado: (2019)

Enzalutamide: a new indication for nonmetastatic castration-resistant prostate cancer
por: Rhea, Logan P, et al.
Publicado: (2019)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2022)

Correction to: Nonmetastatic Castration‑Resistant Prostate Cancer: Current Challenges and Trends
por: Figueiredo, Arnaldo, et al.
Publicado: (2023)

Denosumab: Delay of bone metastasis in men with nonmetastatic castrate-resistant prostate cancer
por: Manger, Jules P., et al.
Publicado: (2012)

Treatment Landscape of Nonmetastatic Castration-Resistant Prostate Cancer: A Window of Opportunity
por: López-Campos, Fernando, et al.
Publicado: (2021)

Apalutamide, enzalutamide, and darolutamide for non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis
por: Mori, Keiichiro, et al.
Publicado: (2020)

Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center
por: McKay, Rana R., et al.
Publicado: (2020)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

Pilot Phase II Trial of Bevacizumab Monotherapy in Nonmetastatic Castrate-Resistant Prostate Cancer
por: Ogita, Shin, et al.
Publicado: (2012)

Nonmetastatic castration-resistant prostate cancer: Novel agents to treat a lethal disease
por: Henriquez, Ivan, et al.
Publicado: (2021)

Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2021)

Time to castration resistance is a novel prognostic factor of cancer-specific survival in patients with nonmetastatic castration-resistant prostate cancer
por: Hakozaki, Yuji, et al.
Publicado: (2022)

Interleukin-23 Represses the Level of Cell Senescence Induced by the Androgen Receptor Antagonists Enzalutamide and Darolutamide in Castration-Resistant Prostate Cancer Cells
por: Gupta, Siddharth, et al.
Publicado: (2020)

Apalutamide Compared with Darolutamide for the Treatment of Non-metastatic Castration-Resistant Prostate Cancer: Efficacy and Tolerability in a Matching-Adjusted Indirect Comparison
por: Chowdhury, Simon, et al.
Publicado: (2021)

Correction to: Real-world use of enzalutamide in men with nonmetastatic castration-resistant prostate cancer in Japan
por: Yokomizo, Akira, et al.
Publicado: (2022)

Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors
por: Saad, Fred, et al.
Publicado: (2021)

Association of Molecular Subtypes With Differential Outcome to Apalutamide Treatment in Nonmetastatic Castration-Resistant Prostate Cancer
por: Feng, Felix Y., et al.
Publicado: (2021)

Nonmetastatic castration‐resistant prostate cancer treated with salvage focal brachytherapy after external beam radiotherapy
por: Yoshida, Soichiro, et al.
Publicado: (2021)

Understanding Treatment Strategies and Preferences in Nonmetastatic Castration-Resistant Prostate Cancer From the Japanese Physician Perspective
por: Suzuki, Kazuhiro, et al.
Publicado: (2021)

Budget Impact of Enzalutamide for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer
por: Bui, Cat N., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h7bnfeg4vmu2qje4ogavrr4sff